Overview of current and future systemic therapy for metastatic renal cell carcinoma

Takahiro Osawa, ario takeuchi, Takahiro Kojima, Nobuo Shinohara, Masatoshi Eto, Hiroyuki Nishiyama

Research output: Contribution to journalArticle

Abstract

Since the 2000s, there have been dramatic advances in the treatment of metastatic renal cell carcinoma (mRCC), including drugs targeting vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways. The first VEGF inhibitors approved for mRCC were sorafenib and sunitinib. Subsequently, two mTOR inhibitors (everolimus and temsirolimus) and other VEGF inhibitors (pazopanib and axitinib) were approved. Overall survival (OS) of mRCC patients has significantly increased during this period. Two novel VEGF inhibitors have recently been approved overseas, including cabozantinib and lenvatinib. Additionally, the recent advent of immunotherapy with checkpoint inhibitors has led to significant changes in the treatment of mRCC. The PD-1 inhibitor nivolumab improved the OS rate of patients with mRCC following VEGF inhibitors. Moreover, the CheckMate 214 trial demonstrated the benefit of nivolumab plus ipilimumab combination therapy in OS and objective response rate in treatment-naive intermediate- and poor-risk mRCC. In this review, current evidence related to the clinical use of targeted therapies and checkpoint inhibitors for the treatment of patients with mRCC is discussed. In addition, we review ongoing trials investigating combinations of checkpoint inhibitors with targeted agents and the identification of biomarkers to guide patient selection and enable individualization of therapy.

Original languageEnglish
Pages (from-to)395-403
Number of pages9
JournalJapanese journal of clinical oncology
Volume49
Issue number5
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Renal Cell Carcinoma
Vascular Endothelial Growth Factor A
Sirolimus
Therapeutics
Survival
Drug Delivery Systems
Immunotherapy
Patient Selection
Survival Rate
Biomarkers

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Overview of current and future systemic therapy for metastatic renal cell carcinoma. / Osawa, Takahiro; takeuchi, ario; Kojima, Takahiro; Shinohara, Nobuo; Eto, Masatoshi; Nishiyama, Hiroyuki.

In: Japanese journal of clinical oncology, Vol. 49, No. 5, 01.01.2019, p. 395-403.

Research output: Contribution to journalArticle

Osawa, Takahiro ; takeuchi, ario ; Kojima, Takahiro ; Shinohara, Nobuo ; Eto, Masatoshi ; Nishiyama, Hiroyuki. / Overview of current and future systemic therapy for metastatic renal cell carcinoma. In: Japanese journal of clinical oncology. 2019 ; Vol. 49, No. 5. pp. 395-403.
@article{a95e8a70f4f3403ea1f74b39bcd1d828,
title = "Overview of current and future systemic therapy for metastatic renal cell carcinoma",
abstract = "Since the 2000s, there have been dramatic advances in the treatment of metastatic renal cell carcinoma (mRCC), including drugs targeting vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways. The first VEGF inhibitors approved for mRCC were sorafenib and sunitinib. Subsequently, two mTOR inhibitors (everolimus and temsirolimus) and other VEGF inhibitors (pazopanib and axitinib) were approved. Overall survival (OS) of mRCC patients has significantly increased during this period. Two novel VEGF inhibitors have recently been approved overseas, including cabozantinib and lenvatinib. Additionally, the recent advent of immunotherapy with checkpoint inhibitors has led to significant changes in the treatment of mRCC. The PD-1 inhibitor nivolumab improved the OS rate of patients with mRCC following VEGF inhibitors. Moreover, the CheckMate 214 trial demonstrated the benefit of nivolumab plus ipilimumab combination therapy in OS and objective response rate in treatment-naive intermediate- and poor-risk mRCC. In this review, current evidence related to the clinical use of targeted therapies and checkpoint inhibitors for the treatment of patients with mRCC is discussed. In addition, we review ongoing trials investigating combinations of checkpoint inhibitors with targeted agents and the identification of biomarkers to guide patient selection and enable individualization of therapy.",
author = "Takahiro Osawa and ario takeuchi and Takahiro Kojima and Nobuo Shinohara and Masatoshi Eto and Hiroyuki Nishiyama",
year = "2019",
month = "1",
day = "1",
doi = "10.1093/jjco/hyz013",
language = "English",
volume = "49",
pages = "395--403",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Overview of current and future systemic therapy for metastatic renal cell carcinoma

AU - Osawa, Takahiro

AU - takeuchi, ario

AU - Kojima, Takahiro

AU - Shinohara, Nobuo

AU - Eto, Masatoshi

AU - Nishiyama, Hiroyuki

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Since the 2000s, there have been dramatic advances in the treatment of metastatic renal cell carcinoma (mRCC), including drugs targeting vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways. The first VEGF inhibitors approved for mRCC were sorafenib and sunitinib. Subsequently, two mTOR inhibitors (everolimus and temsirolimus) and other VEGF inhibitors (pazopanib and axitinib) were approved. Overall survival (OS) of mRCC patients has significantly increased during this period. Two novel VEGF inhibitors have recently been approved overseas, including cabozantinib and lenvatinib. Additionally, the recent advent of immunotherapy with checkpoint inhibitors has led to significant changes in the treatment of mRCC. The PD-1 inhibitor nivolumab improved the OS rate of patients with mRCC following VEGF inhibitors. Moreover, the CheckMate 214 trial demonstrated the benefit of nivolumab plus ipilimumab combination therapy in OS and objective response rate in treatment-naive intermediate- and poor-risk mRCC. In this review, current evidence related to the clinical use of targeted therapies and checkpoint inhibitors for the treatment of patients with mRCC is discussed. In addition, we review ongoing trials investigating combinations of checkpoint inhibitors with targeted agents and the identification of biomarkers to guide patient selection and enable individualization of therapy.

AB - Since the 2000s, there have been dramatic advances in the treatment of metastatic renal cell carcinoma (mRCC), including drugs targeting vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways. The first VEGF inhibitors approved for mRCC were sorafenib and sunitinib. Subsequently, two mTOR inhibitors (everolimus and temsirolimus) and other VEGF inhibitors (pazopanib and axitinib) were approved. Overall survival (OS) of mRCC patients has significantly increased during this period. Two novel VEGF inhibitors have recently been approved overseas, including cabozantinib and lenvatinib. Additionally, the recent advent of immunotherapy with checkpoint inhibitors has led to significant changes in the treatment of mRCC. The PD-1 inhibitor nivolumab improved the OS rate of patients with mRCC following VEGF inhibitors. Moreover, the CheckMate 214 trial demonstrated the benefit of nivolumab plus ipilimumab combination therapy in OS and objective response rate in treatment-naive intermediate- and poor-risk mRCC. In this review, current evidence related to the clinical use of targeted therapies and checkpoint inhibitors for the treatment of patients with mRCC is discussed. In addition, we review ongoing trials investigating combinations of checkpoint inhibitors with targeted agents and the identification of biomarkers to guide patient selection and enable individualization of therapy.

UR - http://www.scopus.com/inward/record.url?scp=85067611990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067611990&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyz013

DO - 10.1093/jjco/hyz013

M3 - Article

VL - 49

SP - 395

EP - 403

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 5

ER -